The global congenital hyperinsulinism treatment market is set to reach USD 100 million by 2023 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033, accumulating a market value of USD 179.08 million. Between 2017 and 2022, the market recorded a CAGR of 4%.
The increasing incidence of Congenital Hyperinsulinism disease, affecting around 1 in 50,000 newborns, is driving the market growth. The World Health Organization (WHO) and other organizations are creating awareness about Congenital Hyperinsulinism treatment, further contributing to market growth.
During the forecast period, North America is expected to hold a market share of approximately 25% due to the rising prevalence of the disease in the region, technological advancements in healthcare, and efficient treatments being introduced.
Startups like Xinvento, a biotech company established in 2021 by CEO Claudine van der Sande, who has a son diagnosed with Congenital Hyperinsulinism (CHI), are playing a significant role in the market. Recently, Xinvento completed a seed funding round, which will enable the company to design and test its proprietary molecules in relevant pre-clinical models to identify potential drug candidates.
Key Takeaways from the Market Study
- From 2017 to 2022, the Congenital Hyperinsulinism Treatment market grew at a CAGR of 4%.
- The global Congenital Hyperinsulinism Treatment market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Congenital Hyperinsulinism Treatment Market is expected to reach US$ 179.08 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 25% market share for the Congenital Hyperinsulinism Treatment market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in the developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.” says an FMI analyst
Market Competition
Key players in the Congenital Hyperinsulinism Treatment market are Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, and Xeris Pharmaceuticals, Inc.
- In September 2022, Novo Nordisk and Microsoft entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities. Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s R&D.
More Insights Available:
Europe is also expected to witness significant growth in the Congenital Hyperinsulinism market. The region has a well-established healthcare system and a large patient pool, which is expected to drive market growth. Furthermore, increasing investments by pharmaceutical companies in the region, along with the growing number of research and development activities, are expected to fuel market growth.
Key Segments Profiled in the Congenital Hyperinsulinism Industry Survey
Treatment Method:
- Drug Therapy
- Diazoxide
- Octreotide
- Glucagon
- Others
- Surgery
Application:
- Hospitals
- Clinics
- Others
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
